These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 11502776)

  • 1. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.
    Komiya I; Yamada T; Sato A; Kouki T; Nishimori T; Takasu N
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3540-4. PubMed ID: 11502776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease.
    Yamada T; Komiya I; Miyahara Y; Komatsu M; Shima I; Inazawa T; Aizawa T
    Endocr J; 2006 Dec; 53(6):783-8. PubMed ID: 16983180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease.
    Sato A; Takemura Y; Yamada T; Ohtsuka H; Sakai H; Miyahara Y; Aizawa T; Terao A; Onuma S; Junen K; Kanamori A; Nakamura Y; Tejima E; Ito Y; Kamijo K
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3602-5. PubMed ID: 10523002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease.
    Nagasaki T; Inaba M; Kumeda Y; Fujiwara-Ueda M; Hiura Y; Nishizawa Y
    Biomed Pharmacother; 2007 Sep; 61(8):472-6. PubMed ID: 17420111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
    J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
    Huang CN; Hsu TC; Chou HH; Tsay GJ
    J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves' disease.
    Liu X; Qiang W; Liu X; Liu L; Liu S; Gao A; Gao S; Shi B
    Exp Clin Endocrinol Diabetes; 2014 Nov; 122(10):564-7. PubMed ID: 25140995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease.
    Rittmaster RS; Abbott EC; Douglas R; Givner ML; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1998 Mar; 83(3):814-8. PubMed ID: 9506733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
    Reinwein D; Benker G; Lazarus JH; Alexander WD
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
    Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A
    Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
    Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
    Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.
    Kubota S; Takata K; Arishima T; Ohye H; Nishihara E; Kudo T; Ito M; Fukata S; Amino N; Miyauchi A
    Thyroid; 2008 Jan; 18(1):63-6. PubMed ID: 18302519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.